Shanghai Fulgent Biotech has struck an agreement with Japan’s Towako Group Shanghai to collaborate in genetic testing and devising reproductive health technology, the Shanghai-based trade and technology firm said in a statement yesterday.
They will use clinical big data in markets across Asia Pacific and promote technology flows and cooperation between China and Japan to apply molecular diagnosis in reproductive medicine through multi-level exchanges, per the statement. The key reproductive health product lines of Fulgent Biotech, which Guangdong province-based reagent maker Xilong Scientific controls, will debut in markets throughout the Asia Pacific region.
Towako is a global fertility hospital chain that operates 17 Kato Clinics in Japan, Southeast Asia, the US and China. It is best known for its ‘micro-stimulation’ and ‘natural-cycle egg retrieval’ techniques and an exceptionally high in vitro fertilization success rate. The firm processes more than 50,000 IVF cases each year.
Their cooperative business thus seems set to be fruitful and multiply.
Source: yicaiglobal.com
